Pfizer announces leadership team for combined company after proposed Allergan merger

Pfizer announced in a press release its executive leadership team for the combined Pfizer and Allergan business following the close of the proposed merger of the companies.

Through the closing of the transaction, Pfizer’s Global Innovative Pharma (GIP) business and its Vaccines Oncology and Consumer (VOC) business will operate separately under Albert Bourla, currently group president of VOC, according to the release. When the transaction is complete, the VOC and GIP businesses will combine, with Bourla becoming group president, Global Innovative Pharma, leading the combined businesses, according to the release.

Geno Germano, group president of Global Innovative Pharma Business, will be leaving the company, according to the release.

A new operating segment named Global Specialty and Consumer Brands will be part of the combined company, which will include Pfizer’s Consumer Healthcare unit and Allergan’s ophthalmology and aesthetic business, and Botox Therapeutic and Cosmetic, according to the release. Bill Meury, who is currently executive vice president and president of Brandied Pharma at Allergan, will become group president, Global Specialty and Consumer Brands of Pfizer, according to the release.

Upon completion of the proposed merger, Pfizer will manage the company’s commercial operations through two business: the Innovative Products business and an Established Products business. John Young, group president, Global Established Pharma, will lead the Established Products business, which includes legacy Hospira commercial operations.

As previously announced, Brent Saunders will become president and chief operating officer of the combined company. Ian Read will remain chairman and chief executive officer of Pfizer, according to the release.

Bourla; Meury; Young; Tony Maddaluna, executive vice president, and president, Pfizer Global Supply; and Laurie Olson, executive vice president, Strategy, Portfolio and Commercial Operation; will report to Saunders upon completion of the merger, according to the release.

Pfizer and Allergan will continue to operate as two separate companies until the completion of the proposed merger, which is expected in the second half of 2016 and is subject to regulatory conditions, according to the release.

Reference: www.pfizer.com